Aldosterone synthase inhibition: a novel bullet to fight cardiovascular–kidney–metabolic syndrome
Journal of Molecular Endocrinology · 2025
DOI: 10.1530/jme-25-0047 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Molecular Endocrinology, 2025. Verfasst von Jonatan Barrera-Chimal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Centre affilié à l'Université de Montréal, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP11B2, Metabolic Syndrome, Cardiovascular Diseases, Enzyme Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 125 Literaturangaben.
Abstract (Originalsprache)
Aldosterone is synthesized by the CYP11B2 enzyme, primarily in the zona glomerulosa of the adrenal gland. It exerts its classical effects on sodium and water balance in the renal distal nephron through binding to the mineralocorticoid receptor (MR). Excess aldosterone production or overactivation of the MR outside the distal nephron leads to cardiac, renal, and vascular injury by increasing oxidative stress and activating the inflammatory and fibrotic pathways. MR antagonists (MRAs) have proved effective at decreasing organ damage and the deleterious effects of excess aldosterone/MR activation. However, MRAs do not fully block the non-genomic effects of aldosterone, which may contribute to residual risks. CYP11B2 inhibition has emerged as an additional therapeutic approach to decreasing the deleterious genomic and non-genomic effects of aldosterone. The development of specific aldosterone synthase inhibitors (ASi) has proved challenging due to the considerable similarity between aldosterone synthase and 11β-hydroxylase, an enzyme encoded by the CYP11B1 gene that catalyzes cortisol synthesis. In this review, we summarize the latest developments on preclinical evidence and clinical trials for ASi and explore the potential clinical advantages of ASi.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Centre affilié à l'Université de Montréal, Montréal, Québec, Canada.
- Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- INSERM, UMRS 1166, Hôpital La Pitié Salpetriere, Sorbonne Université, Paris, France.
- Université de Lorraine, INSERM Centre d'Investigations Cliniques-Plurithématique 1433, UMR 1116, CHRU de Nancy, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT, Nancy, France.
ORCID-Profile: Jonatan Barrera-Chimal
Zitieren
APA
Barrera-Chimal, J., Vaidya, A., & Jaisser, F. (2025). Aldosterone synthase inhibition: a novel bullet to fight cardiovascular–kidney–metabolic syndrome. Journal of Molecular Endocrinology. https://doi.org/10.1530/jme-25-0047
Vancouver
Barrera-Chimal J, Vaidya A, Jaisser F. Aldosterone synthase inhibition: a novel bullet to fight cardiovascular–kidney–metabolic syndrome. Journal of Molecular Endocrinology. 2025. doi:10.1530/jme-25-0047
BibTeX
@article{BarreraChimal2025,
author = {Barrera-Chimal, Jonatan and Vaidya, Anand and Jaisser, Frederic},
title = {Aldosterone synthase inhibition: a novel bullet to fight cardiovascular–kidney–metabolic syndrome},
journal = {Journal of Molecular Endocrinology},
year = {2025},
doi = {10.1530/jme-25-0047}
}
EUVIMED